Cover Image
市場調查報告書

治療層級概要:乾癬 - 斑塊型乾癬 & 乾癬性關節炎 : 轉換未來的治療範例的新口服藥及生技藥品

Psoriasis - Plaque Psoriasis & Psoriatic Arthritis : Novel Oral drugs and Biologics to Change Future Treatment Paradigm

出版商 MP Advisors 商品編碼 296611
出版日期 內容資訊 英文 55 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
治療層級概要:乾癬 - 斑塊型乾癬 & 乾癬性關節炎 : 轉換未來的治療範例的新口服藥及生技藥品 Psoriasis - Plaque Psoriasis & Psoriatic Arthritis : Novel Oral drugs and Biologics to Change Future Treatment Paradigm
出版日期: 2014年02月25日 內容資訊: 英文 55 Pages
簡介

本報告提供乾癬的治療開發平台的口服、注射及局部藥物的相關調查、臨床實驗資料比較、商業性可能性分析,為您概述為以下內容。

第1章 摘要整理

第2章 乾癬的未滿足需求

  • 抗TNF的限制
  • 有更佳功效、安全性輪廓的新藥物空間

第3章 特定的未滿足需求、新的治療方法

  • 斑塊型乾癬
  • 乾癬性關節炎

第4章 開發平台:生技藥品

  • IL-12 及 IL-23 抑制劑
  • 白細胞介素-17 (IL-17) 及 受體 (IL-17RA)
  • 其他標的

第5章 開發平台:口服療法

  • JAK-STAT標的
  • PDE4(PDE4)抑制劑
  • 其他標的

第6章 開發平台:局部療法

  • M518101
  • CT327
  • DRM02
  • Xantryl
  • INCB18424
  • AN2728
  • MOL4249
  • DLX105

第7章 商業性展望

第8章 疾病概要

第9章 目前治療選項

第10章 PsA的治療指南

圖表

目錄
Product Code: TC14022401

Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded considerably and improved patients' pain, function, and quality of life. Approved biologics fill in a critical unmet need of limited efficacy of DMARDs; however, as in most cases one drug does not fit the bill for all the patients. The lack of targeted immune therapies other than TNF-α inhibitors in Psoriasis signals opportunities for drug developers to bring agents to market that offer treatment alternatives (Anti-IL-17, IL-13, JAK, PDE4 inhibitors, etc). Pfizer launched the first oral Rheumatoid Arthritis (RA) drug -Xeljanz (tofacitinib/ CP-690,550, JAK 1/3 inhibitor) in 2012 for pts with moderately to severely active RA who are inadequate responder or intolerant to Methotrexate (MTX) at a price almost at par with biologics. In the last couple of years, the face of healthcare has been changing due to challenges - quality and its affordability and accessibility to the providers and patients.

We believe there is an ample room for an efficacious affordable therapy to tap the mild to moderate RA pts population where biologics have not made a dent and expect few potential launches in 2014-15 (OTEZLA - apremilast, Xeljanz - tofacitinib) and onwards. In this report, we highlight the novel targets - oral, injectables, and topical drugs in the pipeline for the treatment of Psoriasis, compare their clinical trials data, and their commercial potential!

Table of Contents

1. Executive Summary

2. Unmet Need in Psoriasis

  • 1. Limitations of Anti-TNFs
  • 2. Scope for Entrants with Better Efficacy and Safety Profiles

3. Specific Unmet Need and Emerging Therapies

  • 1. Plaque Psoriasis
  • 2. Psoriatic Arthritis

4. Pipeline - Biologics Products

  • 1. IL-12 and IL-23 inhibitors
    • 1. Stelara
    • 2. tildrakizumab (MK-3222/ SCH 900222)
    • 3. Guselkumab (CNTO 1959)
    • 4. Fezakinumab (ILV-094)
  • 2. Interleukin-17 (IL-17) and Receptor (IL-17RA)
    • 1. Secukinumab
    • 2. Ixekizumab (LY2439821)
    • 3. Brodalumab (AMG 827)
  • 3. Other Targets
    • 1. Cimzia
    • 2. Itolizumab
    • 3. Tregalizumab

5. Pipeline - Oral Treatment

  • 1. Targeting JAK-STATs
    • 1. Tofacitinib
    • 2. LY3009104
    • 3. INCB39110
    • 4. ASP015K
    • 5. GSK2586184
  • 2. Phosphodiesterases 4 (PDE4) Inhibitor
    • 1. OTEZLA
  • 3. Other Targets
    • 1. Sotrastaurin
    • 2. LAS41008
    • 3. Voclosporin
    • 4. LLL 3348
    • 5. CF101
    • 6. Ponesimod
    • 7. VB-201
    • 8. FP187
    • 9. GSK-2245840
    • 10. IMO-8400

6. Pipeline - Topical Treatments

  • 1. M518101
  • 2. CT327
  • 3. DRM02
  • 4. Xantryl
  • 5. INCB18424
  • 6. AN2728
  • 7. MOL4249
  • 8. DLX105

7. Commercial Outlook

8. Disease Overview

  • 1. Etiology and Pathophysiology of Psoriasis
  • 2. Types of Psoriasis
  • 3. Treatment Efficacy Tools

9. Current Treatment Options

10. Treatment Guidelines For PsA

TABLES

  • 1 Approved/ Marketed Products
  • 2
    • A. Psoriasis' Pipeline: Small Molecules - Oral/ Injectable
    • B. Psoriasis' Pipeline: Topical
  • 3 Psoriasis' Pipeline: Biologics
  • 4 Select Late- & Mid-Stage Pipeline: Plaque Psoriasis
  • 5 Select Late- & Mid-Stage Pipeline: Psoriatic Arthritis
  • 6 Ixekizumab: Phase III Clinical Trial Designs
  • 7 Brodalumab: Phase III Clinical Trial Designs
  • 8 Clinical Data Comparison: Plaque Psoriasis - Biologics
  • 9
    • A. Tofacitinib: PASI Improvement from Baseline
    • B. Tofacitinib: Improvement in Quality-of-Life (QOL) Measures
  • 10 Other Targets in Clinical Development for RA
  • 11 Genes Associated with Psoriasis Susceptibility
  • 12 Competitive Landscape: Plaque Psoriasis
  • 13 Competitive Landscape: Psoriatic Arthritis

FIGURES

  • 1 PFE's Xeljanz Launch vs. Other Recent RA Launches
  • 2 The Structure and Function of the Cytokines IL-12 And IL-23
  • 3 Clinical Data: ACCEPT - Head-To-Head Trial with Enbrel
  • 4 MK-3222Neutralizes IL-23, Specifically
  • 5 Immunology and Immunotherapeutic Targets of Psoriasis
  • 6 IL-17-Induced Signaling Pathways
  • 7 Ixekizumab: Clinical Response (PASI And sPGA) @ week 20
  • 8 Itolizumab Value Proposition with Marketed Products
  • 9 Regulation of JAK-STAT Signaling
  • 10 INCB39110: Response Rate - Exploratory Efficacy Analyses
  • 11 ASP015K - Changes from Baseline in PASI at Day 42
  • 12 PDE Inhibitors Crosstalk
  • 13 AEB071 - PASI 75 Reductions Compared with Baseline
  • 14 DRM02- Novel Mechanism of Action
  • 15 DLX105 - PhIa Results (PASI Changes @ Day 14)
  • 16 Psoriasis Treatment Ladder (Schematic)
  • 17 US Psoriasis Market Estimation
  • 18 Proposed Schema of the Evolution of A Psoriatic Lesion
  • 19 Distribution of Psoriasis Severity
  • 20 Use of Therapies Depending on the Disease Severity
  • 21 Targeted Therapy Classification Based on Pathogenesis
  • 22 Comparison of GRAPPA and AAD Treatment Guidelines
Back to Top